Insmed to Unveil New Respiratory Data at CHEST and IDWeek 2026…

Event summary

Insmed will present new data across its respiratory portfolio at CHEST 2026 and IDWeek 2026, including late-breaking abstracts on TPIP for PAH and PH-ILD.
Phase 3b ENCORE study findings on ARIKAYCE will examine amikacin and macrolide resistance development in MAC lung disease patients.
Post hoc analysis of the Phase 3 ASPEN study of BRINSUPRI will provide insights on bronchiectasis management.
Presentations will take place from October 18–24, 2026, in Phoenix and Washington, D.C.

The big picture

Insmed's presentations at CHEST 2026 and IDWeek 2026 highlight its strategic focus on advancing respiratory therapies, particularly in areas with high unmet medical needs like PAH, PH-ILD, and MAC lung disease. The company's proprietary technologies, such as PULMOVANCE liposomal technology and TPIP, position it as a key player in the respiratory health sector. The upcoming data could significantly influence the competitive landscape and regulatory pathways for these therapies.

What we're watching

Clinical Efficacy: How the new data on TPIP and ARIKAYCE will impact their regulatory approval and market positioning.
Market Expansion: Whether Insmed can leverage these findings to expand into new therapeutic areas within respiratory health.
Competitive Dynamics: The pace at which competitors will respond to Insmed's advancements in respiratory therapies.